HealthTech Arkansas announced today that it has hired Priya Bargoti as Clinical Trials Manager for the BioAR Trial accelerator program. In this role, Bargoti will coordinate and facilitate clinical trials between BioAR Trial’s participating early-stage biotherapeutics companies and the seven sites in Arkansas where they will conduct clinical trials. Bargoti previously worked for Department of Defense agencies – the Defense Health Agency and the Navy Medical Research Center – managing projects in strategic data analysis and operational management.
BioAR Trial was created by HealthTech Arkansas and SymBiosis Capital Management, LLC to help biotherapeutics companies in late pre-clinical and early clinical stages of development bring groundbreaking therapies to market faster, while increasing Arkansans’ access to cutting-edge clinical care and innovative medicines. This effort aligns with HealthTech Arkansas’s mission to identify and bring superior healthcare technologies to Arkansas to benefit the state’s providers.
“With 14 years of broad clinical trials experience with sites, sponsors and CROs, Priya brings an impressive set of skills to our organization,” said Jeff Stinson, director of HealthTech Arkansas. “I can’t wait to share her formidable talents with the BioAR Trial cohort companies and our sites in Arkansas as we strive to deliver outstanding clinical trials experiences.”
“I look forward to joining the dynamic team at HealthTech Arkansas and supporting the organization’s mission to increase access to innovative care in Arkansas. I aim to form strong bonds with providers and implement efficient methodologies to ensure successful administration of the clinical trials in the BioAR Trial accelerator program,” said Bargoti.
“We are thrilled to welcome Priya, who brings a deep expertise in managing clinical trials, to the BioAR team,” said Jahan Ali, Vice President of Business Development at SymBiosis. “Her experience will be an asset to the program and to the participating companies.”
The application for BioAR Trial is open through January 15, 2023. Companies from around the world are invited to apply to participate in BioAR Trial, which will focus on deploying advanced and emerging therapeutic modalities — such as precision medicines, biologics, cell therapies, and genetic medicines — to treat serious and life-threatening diseases in oncology, immune disorders, and cardio-metabolic disease. BioAR Trial’s first cohort of five companies will begin in April 2023. More information and a link to the application can be found at bioarkansas.co/trial.
ABOUT HEALTHTECH ARKANSAS
HealthTech Arkansas helps to drive innovation for healthcare provider organizations through its accelerator programs and through internal innovation programming. Its flagship accelerator, HeartX, recruits worldwide for the most accomplished cardiovascular-focused startups in the areas of digital health, medical devices, and diagnostic platforms. Those companies accepted into the program are guaranteed at least two pilot projects or clinical trials from among the ten largest hospitals and health systems in Arkansas. More information can be found at HealthTechArkansas.com.
ABOUT SYMBIOSIS CAPITAL MANAGEMENT, LLC
SymBiosis is an investment firm focused on advancing biotherapeutics innovations for serious and life-threatening diseases. The firm invests in groundbreaking medicines across disease area, financing stage, and geography, with a focus on programs in, or about to enter, human trials. SymBiosis currently manages a portfolio of more than 30 investments and has significant, long-term capital commitments to fund future investments. For more information, please visit www.symbiosis.vc or follow us on LinkedIn.